bintrafusp alfa + carboplatin + paclitaxel + bevacizumab

This is a **combination regimen** comprising the following drugs: - **bintrafusp alfa**: a bifunctional fusion protein combining the extracellular domain of transforming growth factor β (TGF-β) receptor II (acting as a TGF-β trap) fused to a human IgG1 antibody that blocks programmed death-ligand 1 (PD-L1). Its mechanism involves dual inhibition of TGF-β and PD-L1 pathways, leading to immunomodulation within the tumor microenvironment and increased antitumor activity[1][2][4][5]. - **carboplatin**: a platinum-based chemotherapeutic agent causing DNA crosslinking, leading to apoptosis in rapidly dividing cells. - **paclitaxel**: a chemotherapeutic that stabilizes microtubules, preventing cell division and leading to cancer cell death. - **bevacizumab**: a humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A), which inhibits angiogenesis crucial for tumor growth[3][6]. These agents are typically combined to enhance antitumor response through complementary mechanisms: immunomodulation, cytotoxicity, and anti-angiogenesis.

Brand names

None known for the combination

Other names

None known for the combination